Navigation Links
Study Looks At Cost-Effectiveness of ECG in Hyperactive Kids
Date:3/8/2010

Analysis compared three strategies for preventing sudden cardiac death from stimulant medication

MONDAY, March 8 (HealthDay News) -- Electrocardiogram screening to check for heart problems in hyperactive children before prescribing stimulant medications may help identify those at risk, but is only borderline cost-effective compared to the current practice of taking a patient history and doing a physical examination, a new study shows.

Stimulant medications -- such as Ritalin, Concerta and Adderall -- that are used to treat attention-deficit/hyperactivity disorder boost pulse rate and may increase the risk of sudden cardiac death in children with some types of heart conditions.

In this study, U.S. National Institutes of Health researchers used a cost-effectiveness model to compare three strategies:

  • Strategy 1. Current standard of care -- a history, physical exam and referral of children with potential problems to a cardiologist.
  • Strategy 2. Conduct an ECG only on children with a normal history and physical, and refer those with suspicious findings on either the history/physical or ECG to a cardiologist. Compared to strategy 1, this approach would save an additional 13 children from sudden cardiac death for every 400,000 children screened. The cost would be $1.6 million per additional life saved and an estimated $39,300 per quality-adjusted life year saved.
  • Strategy 3. Conduct an ECG on all children, as well as a history and physical, and refer only those with an abnormal ECG to a cardiologist. Compared to strategy 1, this approach would also save an additional 13 children from sudden cardiac death for every 400,000 who are screened. The cost would be $1.2 million per additional life saved and about $27,200 per quality-adjusted life year saved.

Lives typically would be saved by barring at-risk children from playing sports, the researchers said.

"We're not making a recommendation, but providing one type of analysis so others can determine what makes sense in the real world," study co-author Dr. Jonathan Kaltman, a medical officer in the heart development and structural diseases branch of the U.S. National Heart, Lung, and Blood Institute, said in a news release.

The study findings are published in the March 8 online edition of the journal Circulation.

"Preventing sudden cardiac death in children is an important issue," Dr. Paul Matherne, chair of the American Heart Association's Council on Cardiovascular Disease in the Young, said in the news release. "While this study has limitations and is not conclusive, it does offer new approaches and insights that add to our understanding of preventing sudden death. Importantly, it highlights the need for more research into both screening to identify children at risk for sudden death, and for developing new therapies to treat these conditions."

More information

The U.S. National Heart, Lung, and Blood Institute has more about sudden cardiac arrest.



-- Robert Preidt



SOURCE: American Heart Association, news release, March 8, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 (the ... adipose filtration technology. The '398 and '324 patents cover methods and systems ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... focused on delivering end-to-end sleep health care at scale, indicates record-breaking adherence ... that adherence rates for positive airway pressure (PAP) therapy, the most widely utilized ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
Breaking Medicine Technology: